MDMA THERAPY

Therapy research with psychedelics often revolves around grand words such as “breakthrough” or “peak experience.” But beneath those narratives lies a more practical question: which dose produces which effect, how quickly, how long, and how tolerable is it? A recent study into intravenous (IV) DMT as a bolus injection shows just how sharp those questions can become, precisely because DMT in this form of administration acts extremely quickly and briefly. This makes the research methodologically interesting, also for those taking a broader view of therapy research with MDMA or other substances.

It is important to distinguish immediately: this study was conducted with healthy participants and was not designed as a treatment. Therefore, it says nothing definitive about DMT as a therapy, let alone about what “the best therapeutic dose” would be. However, it does provide concrete insights into dosage, expectations, monitoring, and study design. These are themes that also frequently recur in MDMA research and harm reduction.

What exactly did this IV-DMT study investigate?

The researchers primarily wanted to understand how IV DMT behaves as a bolus: how quickly the effects appear, how the intensity changes with the dose, how long the effects last, and how well participants tolerate it. In addition, they examined pharmacokinetics (DMT in the blood) and the role of study design: double-blind and randomized versus open-label with stepwise dose escalation.

The study consisted of two research arms. In the first arm, 20 healthy participants received multiple administrations in random order on a single day: placebo and DMT of 5, 10, 15, and 20 mg, double-blind and placebo-controlled. In the second arm, 16 participants received open-label placebo first, followed by escalating doses in increments of 5 mg, up to a maximum of 25 mg. Participants were allowed to decide after each increment whether they wanted to increase the dose further. All administrations were boluses (20 ml in 45 seconds), with approximately one hour between doses.

An important caveat: participants chose for themselves which arm they participated in. As a result, the two arms cannot be compared as strictly, because self-selection can introduce bias. Nevertheless, the difference between the setups is substantively instructive.

Ultra-fast and short: what does this say about “effective time” in therapy research?

IV-bolus DMT had a very rapid onset in this study. Peak effects were usually reached within 1 to 3 minutes, with the strongest effects occurring primarily in the first 2 minutes. Thereafter, the effects diminished rapidly. The total duration of clear subjective effects ranged roughly between 12 and 30 minutes, depending on the dose.

For therapy research, this raises a design question: if an experience is so brief, where is the “therapeutically useful” time? With longer-acting substances, the emphasis often lies on a longer guided session, followed by integration. With an ultra-short peak, the balance can turn out differently: the intensity and pace can be overwhelming, while the time for guidance during the experience is limited. This is not a judgment that it is “less suitable,” but rather an indication that protocols, setting, and guidance may need to be structured differently.

Dosage is not just “more is more”: the ceiling effect around 15 mg

In the double-blind arm, the effects increased dose-dependently, and even 5 mg was already clearly different from placebo. At the same time, the researchers observed a ceiling effect for peak intensity starting at approximately 15 mg. In practical terms, this means that increasing the dose above that point does not necessarily result in a higher “peak,” but it can lead to a greater total burden, for example, because the intense phase lasts longer or because unpleasant effects occur more frequently.

This is a useful lesson for therapy research in general. A higher dose can exceed a threshold required for clear effects, but thereafter the gains may diminish while the risks increase. In research with psychoactive substances, this is relevant for selecting dose ranges, safety margins, and discontinuation criteria.

Control and expectation: why open-label structuring is often more tolerable

The most striking result was the difference in tolerability between the two designs. In the open-label arm with stepwise escalation, comparable dose levels were perceived on average as less intense and, in particular, less negative than in the double-blind, randomized arm. The researchers report that negative effect ratings in that open-label arm were nearly half lower at comparable doses. This suggests that predictability and perceived control can strongly influence the experience.

This aligns with the well-known principle of set and setting, but here you see it very concretely in a dosing experiment. A participant who knows what is coming, who can get used to it step by step, and who can decide to stop themselves, often experiences less of being “taken by surprise.” This is relevant for therapy research, because a protocol choice (for example, titration versus a fixed high dose) is not only methodological but can also have a psychological impact on safety and outcomes.

Side effects, aftercare and the reality of risks

Overall, the authors assessed the tolerability as acceptable, but there were clear burdensome effects. Blood pressure increased dose-dependently. Frequently reported complaints included headache, weakness, concentration problems, and palpitations. There were also psychologically difficult moments, such as anxiety and loss of control, especially at higher doses.

An important detail from the study is that one participant developed anxiety and panic symptoms afterward and required psychiatric follow-up. It concerns a single case, so no general conclusions can be drawn from it. However, it does show why screening, preparation, guidance, and aftercare are not mere formalities in research. Psychological repercussions can occur even in healthy volunteers and under controlled conditions.

Blinding remains difficult, and that influences therapy research

Blinding was only partially effective. With strong psychoactive effects, participants (and sometimes researchers as well) are quick to guess that no placebo was administered. This is a well-known challenge in psychedelic therapy research: if you know or suspect what you have received, expectation can help influence the outcome. In this study, this underscores once again how important it is to interpret results carefully and, where possible, to use designs that better capture expectation effects.

What does this mean for MDMA, therapy, and harm reduction?

Although DMT and MDMA differ significantly, this research touches upon a shared core: therapeutic research revolves not only around the substance but also around protocol choices. Consider dosing strategy, preparation, the degree of freedom of choice, monitoring, and integration. In MDMA research, too, we see that context and guidance are essential to help cope with difficult experiences, without acting as if intensity is automatically “better.”.

In practice, it is also important to remain realistic about what is and is not currently possible. MDMA sessions can currently only be discussed within the context of scientific research or in clinical practice via harm reduction. This means that while we can explain what is known in studies regarding safety and context, we cannot make individual treatment claims or promise a clinical trajectory.

Those who wish to read more broadly about how MDMA and therapy are discussed in research and context can start on the page about MDMA therapy. And anyone considering a guided session in a harm-reduction context can view the practical steps via sign up for an MDMA session. This is not medical advice, nor is it a guarantee of effect, but it can help clarify expectations, preparation, and safety agreements.

Conclusion

The IV-DMT study shows how fast and powerful a psychedelic experience can be, and that a “higher dose” does not automatically mean a better or higher peak. Perhaps even more importantly, the study makes it tangible that expectation, predictability, and freedom of choice can strongly influence tolerability. For therapy research, this is a useful lesson: it is not only the active substance that matters, but also how you design the protocol, how you prepare participants, and how you mitigate risks with proper guidance and aftercare.

Source: Intravenous DMT gives peak experience at 15 mg.